[Clinical photodynamic diagnosis and therapy efficiency in oropharyngeal cancer].
OBJECTIVE
We studied photodynamic diagnosis (PDD) and therapy (PDT) applicability using NPe6 in with oropharyngeal cancer patients.


METHODS
Of 11 subjects diagnosed with oropharyngeal cancer undergoing PDT and PDD using NPe6, 6 were stage T1 and 5 stage T2. None had nodal or distant metastases. Four hours before PDD, NPe6 (40 mg/mD) was injected intravenously. Under general anesthesia, tumor fluorescence observed by laser irradiation, and marked was followed by PDT and photobleaching was confirmed. Tissue collected from tumor centers confirming NPe6 was then compared to normal tissue specimens and the relationship between NPe6 concentration and treatment effectiveness studied.


RESULTS
Tumor marking enabled us ensure a safety margin because the fluorescence scope exceeded tumor scope to the naked eye. Photobleaching was confirmed in all subjects. NPe6 tumor tissue concentration was 1.57-6.84 microg/g, with a ratio of 2.32-5.69 compared to normal tissue. Treatment achieved complete recovery (CR) in all subjects and shortened hospitalization over other treatment such as radiation.


CONCLUSIONS
PDD using NPe6 clearly benefited oropharyngeal cancer patients, and made PDT more accurate. NPe6 accumulated more than twice the level in tumor tissue than in normal tissue.
Konomi
Ujimoto
U
Department of Otolaryngology, Tokyo Medical University School of Medicine, Tokyo.
Yoshida
Tomoyuki
T
Ito
Hiroyuki
H
Shimizu
Akira
A
Shimizu
Shigetaka
S
Okamoto
Isaku
I
Suzuki
Mamoru
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*
D017319:Photosensitizing Agents; D011166:Porphyrins; C053434:Talaporfin